RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer combo J&J’s first-in-class antibody Talvey (talquetamab-tgvs) is bispecific, binding to the CD3 receptor on the T cell surface to a receptor expressed on the myeloma cells to bring them together, allowing the body’s immune system to kill the cancer.
The accelerated approval was based on a Phase II study. An overall response rate of 73.6% was seen in patients with at least four prior lines of therapy, including a bispecific antibody or CAR-T cell therapy. Response was durable for a median of 9.5 months in the lower dosing group. Median duration of response was not yet reached in the higher dose arm.
ONCY's synergy with bispecifics is even better than with anti-body drug conjugates (ADC) since ADCs are usually loaded with a chemotherapy agent while bispecifics are antibodies with two binding sites directed at two different antigens such as pelareorep + a CD3 surface antigen - which results in a more specific,, more effective and less toxic I/O agent than that of an ADC.